Microbiological properties, classifications and structure-activity relationships of cephalosporins and the importance of fourth generation cephalosporins;Propiedades microbiológicas, clasificación y relación estructura-actividad de cefalosporinas e importancia de las cefalosporinas de cuarta generación

Revista Chilena de Infectologia

Volumn 18, Issue 1, 2001, Pages 7-19

  Sergio Mella, M ^a   Claudia Zemelman, M ^a   Helia Bello, T ^a   Mariana Dominguez, Y ^a   Gerardo Gonzalez, R ^a   Raul Zemelman, Z ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Cefepime; Cephalosporins; Extended spectrum lactamases

Indexed keywords

EID: 52549101493     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. ROLINSON G N. The influence of 6-aminopenicillanic acid on antibiotic development. J Antimicrob Chemother 1988; 22: 5-14.
2. ZEMELMAN R, NORAMBUENA R, VERGARA L, GACITUA R. Los antibióticos -lactámicos: agrupación según su estructura química y sus propiedades bacteriológicas. Rev Méd Chile 1987; 115: 983-91.
3. FRIED J S, HINTHORN D R. The cephalosporins. Dis a Month 1985; 31: 1-60.
4. NEU HC. Structure-activity relations of new -lactam compounds and in vitro activity against common bacteria. Rev Infect Dis 1983; 5 (suppl 2): S319-.
5. NEU H C. Beta-lactam antibiotics structural relationships affecting in vitro activity and pharmacological properties. Rev Infect Dis 1986; 8 (Suppl 3): 237-59
6. NEU H C. Relation of structural properties of betalactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl 2 A): 2-13.
7. SCHOLAR E M, PRATT W B (Eds). The inhibitors of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press. 2000 Nueva York. pp:
8. LOPEZ F, GARRIDO J C. Química y relación estructura-actividad de los antibióticos cefalosporínicos (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.
9. TURNIDGE J D. The pharmacodynamics of -lactams. Clin Infect Dis 1998; 27: 10-22.
10. 10.- CRAIG W A. The future-can we learn from the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.
11. 11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991; 91 (Suppl 6 A): 6A-45S.
12. 12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE C H. Cinética y dinámica de los antibióticos para el clínico. Clin Med Nort Am 1995; 79: 483-500.
13. 13.- DRUSANO G L. Human pharmacodynamics of betalactams, aminoglycosides and their combination. Scand J Infect Dis 1991 (Suppl); 74: 235-48.
14. 14.- MARSHALL W F, BLAIR J E. The cephalosporins. Mayo Clinic Proc 1999; 74: 187-95.
15. 15.- DONOWIRZ G R, MANDELL G L. Beta-lactam antibiotics. N Engl J Med 1988; 318: 490-500.
16. 16.- PAYA E. Ventajas y desventajas de las cefalosporinas orales de segunda y tercera generación. Rev Chil Infect 1997; 14: 233-8.
17. 17.- AMERICAN THORACIC SOCIETY. Guidelines for the initial management of adults with communityacquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26.
18. 18.- BARTLETT J G, BREIMAN R F, MANDELL L A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.
19. 19.- MARRIE T J. Community-acquired pneumonia: epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40
20. 20.- TUNKEL A R, SCHELD W M. Acute meningitis. In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Editorial Churchill Livingstone 2000; 959-96.
21. 21.- AMERICAN THORACIC SOCIETY. Hospitalacquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement. Am J Respir Crit Care Med 1996; 153: 1711-25.
22. 22.- BARTLETT J G, DOWELL S F, MANDELL L A, FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82
23. 23.- KARCHMER A W. Cephalosporins. In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone 2000; 274-99.
24. 24.- ADU A, ARMOUR C L. Drug utilisation review (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.
25. 25.- JONES R N. Important and emerging -lactamase mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis 1998; 31: 461-6.
26. 26.- JARVIS W R, MARTONE W J. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.
27. 27.- LIVERMORE D M. -lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.
28. 28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI D, HAWKEY P M. Evolution and spread of SHV extended-spectrum -lactamases in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.
29. 29.- PODSCHUN R, ULLMAN U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998; 11: 589-603.
30. 30.- PITOUT J D D, SANDERS C C, SANDERS W E. Antimicrobial resistance with focus on -lactam resistance in Gram negative bacilli. Am J Med 1997; 103: 51-9.
31. 31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive care units in 5 european countries. JAMA 1999; 281: 67-71.
32. 32.- CHARREL R N, PAGES J M, DE MICCO P et al. Prevalence of outer membrane porin alteration in -lactamantibiotic-resistant Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.
33. 33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated Amp C -lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563-9.
34. 34.- QUEENAN A M, TORRES-VIERA C, GOLD H et al. SME-type carbapenem-hydrolizing class A -lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000; 44: 3035-9.
35. 35.- COHEN S P, MC MURRY L M, HOOPER D C, WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance (Mar) Escherichia coli selected by tetracycline resistance: decreased drug accumulation asociated with membrane changes in addition to Omp F reduction. Antimicrob Agents Chemother 1989; 33:1318-25.
36. 36.- SANDERS C C. Cefepime: The next generation? Clin Infect Dis 1993; 17: 369-79
37. 37.- GARAU J. The clinical potential of fourth-generation cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.
38. 38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON M G. Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16: 533-9.
39. 39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics 1985; 10: 101-43.
40. 40.- WHEELER W J. Cephalosporins and other betalactam antibiotics. Lloydia. 1977; 40: 519-42.
41. 41.- LOPEZ F, GARRIDO J C. Química y relación estructuraactividad de los antibióticos cefalosporínicos. Rev Col Químico Farmacéutico 1989; 41: 5-14.
42. 42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16: 592-7.
43. 43.- YUK J H, NIGHTINGALE C H, QUINTILIANI R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17: 223-35.
44. 44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime, a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology and structureactivity relationships. J Antimicrob Chemother 1990; 26 (Suppl C): 1-8.
45. 45.- CRITCHLEY I A, BASKER M J, EDMONDSON R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.
46. 46.- CRITCHLEY I A. Catecholic -lactams: facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.
47. 47.- JONES R N, ERWIN M E. In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents Chemother 1992; 36: 233-8.
48. 48.- JONES R N. In vitro activity of Ro 24-6392, a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime. Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.
49. 49.- TOMASZ A. Penicillin-binding proteins and the antibacterial effectiveness of -lactam antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 260-78.
50. 50.- HOLM S E. Interaction between -lactam and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.
51. 51.- MC CULLERS J A, ENGLISH B K, NOVAK R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescet meningitis. J Infect Dis 2000; 181: 369-73.
52. 52.- NIKAIDO H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33: 1831-6.
53. 53.- BARRADELL L B, BRYSON H M. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1994; 47: 471-505.
54. 54.- O'CALLAGHAN C H 1979. Description and classification of the newer cephalosporins and their relationship with the established compounds. J Antimicrob Chemother 5: 635-71
55. 55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother 1990; 26 (Suppl. C): 59-63.
56. 56.- WILLIAMS J D. Classification of cephalosporins. Drugs. 1987; 34 (Suppl 2): 15-22.
57. 57.- WISEMAN L R, LAMB H M. Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997; 57: 117-40.
58. 58.- PECHERE J C, WILSON W, NEU H. Laboratory assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins. J Antimicrob Chemother 1995; 36: 757-71
59. 59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P, TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis), a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36: 185-91.
60. 60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.
61. 61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin in experimental infections in mice. Antimicrob Agents Chemother 1993; 37: 100-5.
62. 62.- WATANABE N A. Newer antipseudomonal cephalosporins. J Chemother 1996; 8 (Suppl 2): 48-56.
63. 63.- ACTOR P, GUARINI J, URI J et al. Disk susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother 1974; 5: 63-7.
64. 64.- UWAYDAH M. Cefazolin in the treatment of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.
65. 65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait teaching hospital. J Chemother 1998; 10: 285-90.
66. 66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract infections in adults. Curr Ther Res 1987; 42: 124-37.
67. 67.- SANDERS C W, GREENBERG R N, MARIER R L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.
68. 68.- STAPLEY E P, JACKSON M, HERNANDEZ S et al. Cephamycins, a new family of -lactam antibiotics I. Production actinomycetes, including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother 1972; 2: 122-31.
69. 69.- COOPER R D G. The carbacephems a new -lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.
70. 70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins, aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.
71. 71.- MEDEIROS A A. Evolution and dissemination of -lactamases accelerated by generation of -lactam antibiotics. Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.
72. 72.- PERRY C M, BROGDEN R N. Cefuroxime axetil: review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1996; 52: 125-58.
73. 73.- SCHAAD U B, SUTER S, GIANELLABORRADORI et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322: 141-7.
74. 74.- KLEIN N C, CUNHA B A. Cefalosporinas de la tercera generación. Clin Med Nort Am 1995; 79: 693-707.
75. 75.- KLUGMAN K P, MADHI S A. Emergence of drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999; 13: 637-46.
76. 76.- RICHARDS D M, BROGDEN R N. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1985; 29: 105-61.
77. 77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.
78. 78.- DALMAU D, LAYRARGUES G P, FENYVES D, WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.
79. 79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer membrane permeability and -lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34: 337-42.
80. 80.- HANCOCK R E W, BELLIDO F. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.
81. 81.- BELLIDO F, PECHERE J C, HANCOCK REW. Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991; 35: 68-72.
82. 82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin. J Antimicrob Chemother 1986; 17: 441-52.
83. 83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO K. -lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.
84. 84.- GARAU J, WILSON W, WOOD M, CARLET J. Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1): 87-101.
85. 85.- KESSLER R E, FUNG-TOMC J. Susceptibility of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over 5-year period. Am J Med 1996; 24 (6 A): 13-9.
86. 86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.
87. 87.- JONES R N. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl 2): 397-404.
88. 88.- LORBER B. Changing patterns of infectious diseases. Am J Med 1988; 84: 569-78.
89. 89.- MOELLERING R C. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130: 155-7.
90. 90.- WILSON W R. The role of fourth-generation cephalosporins in the treatment of serious infectious diseases in hospitalized patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.